Entelo Bio has developed a proprietary platform that integrates clinical networks, wet-lab capabilities and AI to generate high-quality human data and disease models for disorders ranging from chronic age-associated diseases to rare genetic movement conditions. The company positions its work around human physical resilience, using global clinical data inputs to drive AI discovery and then validating predictions in human-centric models. Leadership frames the strategy as operating at the intersection of AI and consumer-driven medicine to de-risk and co-develop new therapeutics with partners. Entelo Bio traces its scientific origins to multi-omics and computational biology research at the University of Oxford’s Botnar Institute for Musculoskeletal Sciences, and its team includes veterans of leading AIxBio companies. With the newly raised $4 million, the company plans to deepen infrastructure, expand partnerships, and advance its platform development to address conditions that affect an estimated 1.7 billion people worldwide.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2026